Mycophenolate Mofetil and New-Onset Systemic Lupus Erythematosus
JAMA Network Open · 2024
DOI: 10.1001/jamanetworkopen.2024.32131 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2024. Verfasst von Yijun You und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Mycophenolic Acid, Lupus Erythematosus, Systemic, Hydroxychloroquine, Prednisone. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Anti–double-stranded DNA (dsDNA) antibody has been reported to have a close relationship with systemic lupus erythematosus (SLE) flares and participates in the pathogenesis of lupus nephritis (LN) as well as causing damage to other organs. However, whether early use of mycophenolate mofetil (MMF) could prevent SLE flares is not clear.
Objective
To assess the efficacy and safety of MMF plus prednisone and hydroxychloroquine sulfate compared with prednisone and hydroxychloroquine sulfate alone in patients with SLE. Design, Setting, and Participants This investigator-initiated, multicenter, observer-blinded randomized clinical trial enrolled 130 participants aged 18 to 65 years and was conducted in 3 hospitals across China. Treatment-naive patients with newly diagnosed SLE, a high titer of anti-dsDNA antibody, and no major organ involvement were included. The study was started September 1, 2018, and the follow-up was completed September 30, 2021. Data were analyzed from December 1, 2021, to March 31, 2022.
Interventions
Patients were randomized 1:1 to receive oral prednisone (0.5 mg/kg/d) and hydroxychloroquine sulfate (5 mg/kg/d) (control group) or prednisone (0.5 mg/kg/d) and hydroxychloroquine sulfate (5 mg/kg/d) plus MMF (500 mg twice daily) (MMF group) for 96 weeks. Main Outcomes and Measures The primary outcome was the proportion of patients presenting with flares according to the Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) Flare Index. The secondary outcomes included the proportion with lupus low disease activity state at week 96, 36-Item Short Form Health Survey scores before and after treatment, proportion of adverse events (AEs), and changes in SLEDAI-2000 scores and prednisone doses.
Results
Among 130 randomized patients (mean [SD] age, 34.5 [12.5] years; 112 [86.2%] women), 119 (91.5%) completed the follow-up. The risk of severe flare was significantly lower in the MMF group (7 of 65 [10.8%]) vs the control group (18 of 65 [27.7%]) (relative risk [RR], 0.39 [95% CI, 0.17-0.87]; P = .01). Additionally, 1 of 65 patients in the MMF group (1.5%) and 9 of 65 in the control group (13.8%) manifested LN (RR, 0.11 [95% CI, 0.01-0.85]; P = .008). Most common serious study drug–related AEs were infections (20 of 65 [30.8%] in the control group and 22 of 65 [33.8%] in the MMF group). Conclusions and Relevance The findings of this randomized clinical trial suggest that MMF may reduce the rate of severe flare and lower the incidence of LN in patients with new-onset SLE and a high titer of anti-dsDNA antibody without major organ involvement. Trial Registration Chinese Clinical Trial Registry: ChiCTR1800017540
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Clinical Research Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Rheumatology and Immunology, First Affiliated Hospital of Wenzhou Medical University, Zhejiang, China.
- Department of Rheumatology and Immunology, Second Affiliated Hospital of Shandong First Medical University, Shandong, China.
- Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zitieren
APA
You, Y., Zhou, Z., Wang, F., Li, J., Liu, H., Cheng, X., Su, Y., Chen, X., Zheng, H., Sun, Y., Shi, H., Hu, Q., Xu, J., Teng, J., Yang, C., & Ye, J. (2024). Mycophenolate Mofetil and New-Onset Systemic Lupus Erythematosus. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.32131
Vancouver
You Y, Zhou Z, Wang F, Li J, Liu H, Cheng X, et al. Mycophenolate Mofetil and New-Onset Systemic Lupus Erythematosus. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.32131
BibTeX
@article{You2024,
author = {You, Yijun and Zhou, Zhuochao and Wang, Fan and Li, Jian and Liu, Honglei and Cheng, Xiaobing and Su, Yutong and Chen, Xiaowei and Zheng, Hui and Sun, Yue and Shi, Hui and Hu, Qiongyi and Xu, Jing and Teng, Jialin and Yang, Chengde and Ye, Junna},
title = {Mycophenolate Mofetil and New-Onset Systemic Lupus Erythematosus},
journal = {JAMA Network Open},
year = {2024},
doi = {10.1001/jamanetworkopen.2024.32131}
}
EUVIMED